Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational... see more

Recent & Breaking News (NDAQ:PMN)

ProMIS Neurosciences (TSX:PMN) files application for new Alzheimer’s vaccine

Jonathon Brown April 10, 2023

ProMIS Neurosciences Announces Submission of Investigational New Drug (IND) Application for Lead Antibody PMN310

GlobeNewswire April 10, 2023

Lead Therapeutic Candidate, PMN310, Demonstrates Enhanced Selectivity for Toxic Oligomers Compared to Other Amyloid-Beta-Directed Antibodies in Poster Presentation at AD/PD 2023

GlobeNewswire March 29, 2023

ProMIS Neurosciences (TSX:PMN) to present at the American Academy of Neurology 2023

Brieanna McCutcheon  March 13, 2023

ProMIS Neurosciences Announces Abstracts Accepted for Presentation at the American Academy of Neurology 2023 Annual Meeting

GlobeNewswire March 13, 2023

ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023

GlobeNewswire March 13, 2023

ProMIS Neurosciences Announces Full Year 2022 Financial Results and Recent Highlights

GlobeNewswire March 8, 2023

Promis Neurosciences to Present at the Oppenheimer 33rd Annual Healthcare Conference

GlobeNewswire March 8, 2023

ProMIS Neurosciences Announces Third Quarter 2022 Financial Results and Recent Highlights

GlobeNewswire November 14, 2022

ProMIS Neurosciences (TSX:PMN) closes US$7.4M private placement

John Ballem  October 12, 2022

ProMIS Neurosciences Announces Closing of US $7.4 Million Private Placement

GlobeNewswire October 12, 2022

ProMIS Neurosciences (TSX:PMN) appoints Dr. Gail Farfel as Chief Executive Officer

John Ballem  September 13, 2022

ProMIS Neurosciences appoints accomplished biopharmaceutical leader, Dr. Gail M. Farfel, as Chief Executive Officer

GlobeNewswire September 13, 2022

ProMIS Neurosciences Announces Second Quarter 2022 Financial and Operating Results

GlobeNewswire August 15, 2022

ProMIS Neurosciences Presents at 2022 Alzheimer's Association International Conference

GlobeNewswire August 2, 2022

ProMIS Neurosciences to Present at 2022 Alzheimer's Association International Conference

GlobeNewswire July 27, 2022

ProMIS Neurosciences (TSX:PMN) to commence trading on Nasdaq

Azuka Onwuka July 8, 2022

ProMIS Neurosciences to Commence Trading on Nasdaq Under the Symbol "PMN"

GlobeNewswire July 8, 2022

ProMIS (TSX:PMN) announces reverse share split to meet Nasdaq listing criteria

Azuka Onwuka June 27, 2022

PROMIS ANNOUNCES REVERSE SHARE SPLIT TO MEET NASDAQ LISTING CRITERIA

GlobeNewswire June 27, 2022